Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis
Zhang Z, Yildirim M, Keskinocak P, Dasthagirisaheb Y, Hinderstein S, Tran K, Crockett M, Burns M, Johnson H, Popstefanija M, Madoff L, Pelton S, Yildirim I. Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis. Vaccine 2025, 56: 127193. PMID: 40318350, DOI: 10.1016/j.vaccine.2025.127193.Peer-Reviewed Original ResearchIncidence rate ratiosInvasive pneumococcal diseaseSickle cell diseaseIncidence ratePost-PCV13 periodCalculated incidence ratesValency vaccinesVaccine effectivenessPneumococcal diseaseHealthy childrenRates of invasive pneumococcal diseasePopulation-basedCell diseaseHealth conditionsRate ratiosNon-PCV13 serotypesPneumococcal vaccine effectivenessVulnerable populationsBootstrapping resamplingIncreased riskHigher IRNon-PCV13Genetic hematological diseasesHematological diseasesVaccine formulations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply